Sputum interleukin-6 level as a marker of severity during acute chest syndrome in children with sickle cell disease.
Br J Haematol
; 205(1): 329-334, 2024 Jul.
Article
en En
| MEDLINE
| ID: mdl-38783629
ABSTRACT
Acute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin-6 (IL-6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL-6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non-invasive) length ≥5 days, bilateral and/or extensive opacities on chest X-ray or erythrocytapheresis requirement. Sputum IL-6 could serve as an ACS severity marker to help identify patients requiring targeted anti-inflammatory treatments such as tocilizumab.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Esputo
/
Índice de Severidad de la Enfermedad
/
Biomarcadores
/
Interleucina-6
/
Síndrome Torácico Agudo
/
Anemia de Células Falciformes
Límite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Año:
2024
Tipo del documento:
Article